Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Therapy

Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study

Abstract

We report the first randomized study assessing the efficacy and safety of daunorubicin (DNR) continuous infusion (CI) compared to the more conventional 30-min infusion (i.v.) in newly diagnosed adult acute lymphoblastic leukemia (ALL). Seventy-seven patients were initially randomized to receive either a 24-h CI DNR (60 mg/m2 days 2–4) (40 patients) or bolus DNR at the same dosage (37 patients) with vincristine (2 mg i.v. days 1, 8, 15) and oral prednisone (60 mg/m2 days 1–15), without hematopoietic growth factor support, as an induction regimen. The distribution of adverse prognostic factors was comparable in the two-induction arm. Acute toxicity was more important in the CI arm. Gram negative infection (9 vs 1 gram negative septicemia, P = 0.01) and infection-related deaths (6 vs 1 deaths, P = NS) occurred more frequently in the CI arm during the induction treatment than in the i.v. arm, leading to the study interruption. Neutropenia but not thrombopenia duration was significantly longer in the CI arm than in the i.v. arm (18 days vs 14 days, P > 0.05 and 16 days vs 12 days, P > 0.05, respectively). Despite a similar CR rate according to the method of DNR administration (68% in the CI DNR arm vs 76% in the i.v. arm after the first course), there was a trend toward higher freedom from relapse (FFR) after DNR CI (48% vs 28% in the i.v. arm at 5 years, P = NS), suggesting that despite this high toxicity, DNR CI may improve the CR quality and decrease further the residual disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Hoelzer DF . Therapy of the newly diagnosed adult with acute lymphoblastic leukemia Hematol Oncol Clin North Am 1993 7: 139–160

    Article  CAS  Google Scholar 

  2. Copelan EA, McGuire EA . The biology and treatment of acute lymphoblastic leukemia in adults Blood 1995 85: 1151–1168

    CAS  PubMed  Google Scholar 

  3. Pui CH, Evans WE . Acute lymphoblastic leukemia N Engl J Med 1998 339: 605–615

    Article  CAS  Google Scholar 

  4. Carlson R, Sikic B . Continuous infusion or bolus injection in cancer chemotherapy Ann Int Med 1983 99: 823–833

    Article  CAS  Google Scholar 

  5. Speth P, Linssen P, De Pauw B, De Witte T . Cellular pharmacokinetics of daunomycin administered as continuous intravenous infusion in the treatment of acute non-lymphocytic leukaemia Br J Haematol 1986 63: 603–605

    Article  Google Scholar 

  6. Garnick M, Weiss G, Steele G, Isreael M, Schade D, Sack M, Frei E . Clinical evaluation of long-term, continuous infusion doxorubicin Cancer Treat Rep 1983 67: 133–142

    CAS  PubMed  Google Scholar 

  7. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Carey RW, Levy RN, Hutchinson J, Raich P, Cooper M, Wiernik P, Anderson J, Holland J . Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B Blood 1984 64: 267–274

    CAS  PubMed  Google Scholar 

  8. Bassan R, Chiodini B, Zucchetti M, Lerede T, Cornelli PE, Cortelazzo S, Barbui T . Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results Haematologica 1998 83: 27–33

    CAS  PubMed  Google Scholar 

  9. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G . Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan- Kettering-New York-II protocol Cancer 1993 72: 3120–3130

    Article  CAS  Google Scholar 

  10. DeGregorio MW, Carrera CJ, Klock JC, Pegelow CH, Wilbur JR . Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia Cancer Treat Rep 1982 66: 2085–2088

    CAS  PubMed  Google Scholar 

  11. Koskela K, Pelliniemi TT, Remes K . VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Leuk Lymphoma 1993 10: 347–351

    Article  CAS  Google Scholar 

  12. Lewis J, Meyers F, Tanaka L . Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukemia Br J Haematol 1985 61: 261–265

    Article  CAS  Google Scholar 

  13. Archimbaud E, Anglaret B, Thomas X, Devaux Y, Ffrench M, Sebban C, Troncy J, Fiere D . Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly Leukemia 1992 6: 776–779

    CAS  PubMed  Google Scholar 

  14. Liso V, Specchia G, Pavone V, Capalbo S, Dione R . Continuous infusion chemotherapy with epirubicin and vincristine in relapsed and refractory acute leukemia Acta Haematol 1990 83: 116–119

    Article  CAS  Google Scholar 

  15. Neuendank A, Hartmann R, Buhrer C, Winterhalter B, Klumper E, Veerman AJ, Henze G . Acute toxicity and effectiveness of idarubicin in childhood acute lymphoblastic leukemia Eur J Haematol 1997 58: 326–332

    Article  CAS  Google Scholar 

  16. Koc Y, Akpek G, Kansu E, Kars A, Tekuzman G, Baltali E, Guler N, Barista I, Gullu I, Ozisik Y, Firat D . Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: results of two consecutive phase II clinical studies Cancer Invest 1998 16: 355–365

    Article  CAS  Google Scholar 

  17. Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, McCredie K, Freireich E . Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia J Clin Oncol 1990 8: 994–1004

    Article  CAS  Google Scholar 

  18. Kantarjian HM, O'Brien S, Smith T, Estey EH, Beran M, Preti A, Pierce S, Keating MJ . Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen Br J Haematol 1994 88: 94–100

    Article  CAS  Google Scholar 

  19. Morland BJ, Shaw PJ . Induction toxicity of a modified Memorial Sloan-Kettering-New York II protocol in children with relapsed acute lymphoblastic leukemia: a single institution study Med Pediatr Oncol 1996 27: 139–144

    Article  CAS  Google Scholar 

  20. Ottmann OG, Hoelzer D . Growth factors in the treatment of acute lymphoblastic leukemia Leuk Res 1998 22: 1171–1178

    Article  CAS  Google Scholar 

  21. Engels EA, Lau J, Barza M . Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis J Clin Oncol 1998 16: 1179–1187

    Article  CAS  Google Scholar 

  22. Hortobagyi GN . Anthracyclines in the treatment of cancer. An overview Drugs 1997 54: 1–7

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hunault-Berger, M., Milpied, N., Bernard, M. et al. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Leukemia 15, 898–902 (2001). https://doi.org/10.1038/sj.leu.2402130

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402130

Keywords

Search

Quick links